Skip to main content

Table 1 Clinicopathological characteristics of LUAD patients from the training and validation sets

From: A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma

Characteristics

Training set (n = 494)

Validation set 1 (n = 226)

Validation set 2 (n = 398)

Number of cases

%

Number of cases

%

Number of cases

%

Median

66 (33–88)

 

61 (30–76)

 

70 (38–89)

 

Age (years)

 ≥ 65

274

55.5

62

27.4

291

73.1

 < 65

220

44.5

164

72.6

107

26.9

Gender

 Male

228

46.2

105

46.5

176

44.2

 Female

266

53.8

121

53.5

222

55.8

Stage

 Stage 3–4

106

21.8

0

0

72

18.3

 Stage 1–2

380

78.2

226

100

321

81.7

Smoking

 Yes

411

85.6

111

49.1

300

90.6

 No

69

14.4

115

50.9

31

9.4

KRAS mutation

 Mutation

  

20

8.8

139

34.9

 Wild-type

  

206

91.1

259

65.1

EGFR mutation

 Mutation

  

127

56.2

41

10.3

 Wild-type

  

99

43.8

357

89.7

T

 T 3–4

64

13

    

 T 1–2

427

87

    

M

 Positive

25

7.1

    

 Negative

325

92.9

    

N

 Positive

164

34

    

 Negative

318

66

   Â